原発性高脂血症の治療におけるGLP-1受容体作動薬の有効性

関連する実験動画

Updated: Feb 26, 2026

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

1.3K

Thao Lam1, Jeffrey N Li1, Hadar Lev-Tov2

  • 1Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1600 NW 10th Ave RMSB 2023A, Miami, FL, 33136-1101, USA.

American journal of clinical dermatology
|February 25, 2026
PubMed
まとめ

No abstract available in PubMed .

さらに関連する動画

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays08:06

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays

Published on: November 10, 2016

8.0K
Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors04:59

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors

Published on: September 27, 2019

13.1K

関連する概念動画

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K